| Name | Compounded Enclomiphene & Branded Enclomiphene (Androxal, Enclomid). |
| Uses | Treatment of secondary hypogonadism in men, testosterone optimization, fertility support. |
| Route Of Administration | Oral (capsules, tablets). |
| Frequency Of Use | Typically once daily, 12.5mg to 25mg per day, with reassessment every 4-6 weeks. |
| Concentration(s) | Oral: 6.25mg, 12.5mg, 25mg capsules or tablets. |
| Maximum Dosage (Day, Wk) | Max 50mg/day, though most cases do not exceed 25mg/day. |
| Contraindications | History of hormone-sensitive cancers, uncontrolled hypertension, active liver disease, pituitary or primary testicular failure, thromboembolic history. |
| Possible Side Effects | Headaches, nausea, visual disturbances, mood swings, increased libido, potential elevation in hematocrit and liver enzymes. |
| Compatibility With Other Treatments/Drugs | Use caution with testosterone replacement therapy (TRT), SERMs, and aromatase inhibitors due to hormonal interactions. |
| Allergies | Check for hypersensitivity to enclomiphene or excipients in compounded formulations. |
| Administration Time | Take in the morning, preferably at the same time each day, with or without food. |
| Dosing/Settings | 12.5mg to 25mg daily; reassess labs (total/free testosterone, estradiol, LH, FSH) at 4-6 weeks. |
| Test Spot Requirement | Not required. |
| Pre-Treatment Guidelines | Baseline hormone panel (testosterone, LH, FSH, estradiol, prolactin, SHBG), liver function test (LFTs), and hematocrit levels. |
| Provider Clearance Guidelines | Ensure no contraindications, confirm hypogonadism diagnosis (low testosterone with inappropriately normal/low LH/FSH). |
| Pre-Treatment Screening Workflow | 1. Verify clinical indication. 2. Assess contraindications. 3. Obtain informed consent. 4. Order baseline labs if not available. |
| What To Do If Adverse Reaction Occurs | For mild symptoms (headache, nausea): Lower dose and reassess. For severe reactions (visual disturbances, thromboembolism risk): Discontinue immediately and consult a physician. |
| Clinic Implementation Guidelines | Confirm prescription, educate patient on proper use, document treatment details in EMR. |
| Photographic Documentation Protocol | Not required. |
| Post-Treatment Care | Monitor hormone panel every 4-6 weeks, adjust dosage based on lab results and clinical response. |
| Additional Documentation Requirements | Signed informed consent, treatment logs, prescription details, and adverse event documentation if applicable. |
| Special Notes | Enclomiphene differs from clomiphene by having selective estrogen receptor modulator (SERM) activity focused on increasing LH/FSH without anti-testosterone effects. |